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816Objective: During the past decade the Ross procedure using the full root has become the predominant surgical
technique. However, progressive autograft dilatation and eventual failure remain a concern. Here we report on the
surgical techniques and results of the subcoronary technique over a 14-year period.
Methods: A total of 501 patients (mean age, 44.9  12.9 years; 117 female; 384 male) were operated on from
June 1994 to December 2007. The follow-up database, with a completeness of 98.2%, was closed on December
2008, comprising of 2931 patient-years with a mean follow-up of 5.9  3.6 years (range, 0.1–14.1 years).
Results: Surgical details are presented. Early and late mortality were 0.4% (n¼ 2) and 4% (n¼ 20), respectively,
valve-related mortality was 1.2% (n¼ 6), whereas the overall survival did not differ from that of the normal pop-
ulation. Neurologic events occurred in 22 patients, major bleeding in 9, autograft endocarditis in 8, and homograft
endocarditis in 10. Freedom from autograft and homograft reoperation was 91.9% at 10 years. For the majority of
patients, hemodynamics was excellent and no root dilatation was observed.
Conclusions: Midterm results after the original subcoronary Ross procedure are excellent, including normal sur-
vival and low risk of valve-related morbidity. Longer-term results are necessary for continuous judgment of the
subcoronary technique. (J Thorac Cardiovasc Surg 2010;140:816-22)Supplemental material is available online.
Video clip is available online.
The pulmonary autograft procedure for the treatment of
aortic valve disease, first performed by Donald Ross1 in
1967, is the only aortic valve replacement procedure that
theoretically provides all the advantages of a viable autolo-
gous tissue valve, achieving almost physiologic aortic valve
hemodynamics and motion2,3 with low incidence of macro-
embolism and microembolism3-6 and without the need for
lifelong anticoagulation. This makes the procedure espe-
cially attractive to young patients, whose quality of life
may be limited by the valve-related morbidity of mechanical
substitutes and the limited durability of biological prosthesese University of Lu¨beck, Department of Cardiac and Thoracic Vascular
ry, Lu¨beck, Germany.
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The Journal of Thoracic and Cardiovascular Surgin this age group.7 Since the publication of excellent results
in the early and late 1990s,4,5,8 a renaissance of this surgical
method has been lately observed.3,9-12
Although the Ross operation was initially performed as
a subcoronary transplant,1 the technical complexity of this
technique made the reproduction of Ross’s initial and late re-
sults1,5 with the subcoronary technique difficult. This led to the
development of the total root replacement technique, in which
the complete aortic root is entirely replaced by the pulmonary
root.4,8,13 This technique has received broad acceptance in
81% of patients of the International Ross Registry.14 How-
ever, concerns have surfaced lately regarding the ability of
the isolated, unsupported pulmonary root to withstand the sys-
temic circulation over time without progressive dilatation,
leading to an unexpectedly increased reoperation rate 7 to 9
years after the initial operation.9,10,15,16 We have performed
the Ross operation with the subcoronary technique since
1994. Here we present a detailed description of the subcoro-
nary surgical technique and our results in 501 patients.17PATIENTS AND METHODS
From June 1994 through December 2007, the subcoronary Ross tech-
nique was performed in 501 consecutive patients, being 9.6% of the total
number of aortic valve procedures in our center within that period. During
this time period, 6 full root Ross procedures were performed (not included in
this study), mainly in patients with severely malformed aortic roots, aortic
roots destroyed by endocarditis, and reoperation after valve-sparing proce-
dures and xenograft implantation. Thirty-three patients operated on with the
root inclusion technique were included in this patient population. Because
we did not find any difference between the root inclusion technique and
the subcoronary technique in this study or in previous studies,3,11,15 we de-
cided to include these patients in the subcoronary population. The operativeery c October 2010
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Dindications were in line with American Heart Association/American Col-
lege of Cardiology guidelines.17 The presence of markedly reduced left ven-
tricular function, extensive coronary artery disease, connective tissue or
active rheumatic disorders, severe deformation of the aortic root anatomy,
or structural defects of the pulmonary valve, as well as intractable systemic
hypertension, were considered contraindications for the Ross procedure. It
is generally our philosophy that the Ross procedure is an extraordinary aor-
tic valve replacement technique besides the commonly used alternatives and
should not be performed if there are any doubts about the anatomy, the tech-
nical feasibility, or the attitude of the patient, the surgeon, or the cardiolo-
gist. Demographics and valve-related preoperative parameters are
presented in Table 1. Early after the operation, antithrombotic treatment
was initiated with aspirin 100 mg per day and low molecular weight heparin
for 1 week. Afterward, aspirin 100 mg per day was maintained for 3 months.
Surgical Technique
The surgical technique evolved mainly over the first 5 years, thereafter be-
ing by and large standardized (see Video 1). Nevertheless, increasing expe-
rience will lead to further modifications. Standard cardiopulmonary bypass
with moderate systemic hypothermia was used. In the first years crystalloid
cardioplegia was applied and later cold blood cardioplegia at 20-minute in-
tervals. A detailed description of the surgical technique including 9 figures
(Figures E1–E9) and a video is provided in the online E-Appendix.
Follow-up
Follow-up visits were performed prospectively on an outpatient basis 1, 3,
6, and 12 months after the operation and annually thereafter by clinical eval-
uation and serial standardized echocardiography.11 All perioperative and post-
operative events were defined according to the latest guidelines (2008) for
reporting mortality and morbidity after cardiac valve interventions.17 Details
of the echocardiographic evaluation have been reported previously.11,18,19
The study database was frozen on December 31, 2008. Follow-up was
98.2% complete at this time. The mean follow-up duration was 5.9 3.6 years
(range, 0.01–14.1 years) with a cumulative follow-up of 2931 patient-years.
Statistical Analysis
Continuous data were expressed as mean  SD. Categorical variables
were presented as absolute numbers and percentages. Estimation of long-
term survival, freedom from morbid events, and valve function was made
by the Kaplan–Meier method with truncation of the data at 12 years (when
only 10% of patients remained at risk) so as to warrant statistical accuracy
and sound conclusions. The survival time of each patient started at the
time of surgery and ended at death (event) or at last follow-up (censoring).
The long-term survival characteristics of the patient cohort were compared
with the survival probabilities of the age- and gender-matched general pop-
ulation obtained from German Life Tables 2004/2006 (www.destatis.de).
The analysis of event-free rates started at the time of operation and ended
at the time of an event (eg, reoperation, thromboembolism, bleeding) or
last follow-up or death (censoring). Statistics for patients with incomplete
follow-up investigations were censored at the time of their last inquiry.
The SPSS 13.0 for Windows statistical software (SPSS, Inc, Chicago, Ill)
was used for all analyses. The authors had full access to the data and take
responsibility for their integrity. Informed consent was obtained from all pa-
tients preoperatively and before each follow-up visit. The local ethics com-
mittee approved the present study (Clinical Trials ID: NCT 00708409).The Journal of Thoracic and CaRESULTS
Mortality
Early mortality. All-cause early (<30 days) mortality was
0.4% (n ¼ 2, owing to refractory ventricular arrhythmias
3 days postoperatively and to a thromboembolic occlusion
of the left main coronary artery 7 days after valve replace-
ment for infective endocarditis). The autograft function
was excellent. No early mortalities occurred in the following
291 procedures.
Valve-related late mortality. Valve-related mortality was
1.2% (6 patients, linearized occurrence rate [LOR] 0.20%/
patient-year): 1 patient with coronary embolism, 1 with
refractory ventricular arrhythmias, 1 with surgically treated
valve endocarditis (primary mitral valve endocarditis, with
eventual involvement of the autograft and homograft), 2
sudden, unexplained deaths (last follow-up examinations
revealed no valvular problems in these patients), and 1 patient
with heart failure with severe regurgitation of all 4 cardiac
valves.
Cardiac death. The number of deaths of cardiac etiology
was 8 (LOR, 0.27%/patient-year). Included are 6 valve-
related deaths and 2 non–valve-related cardiac fatalities.
All-cause mortality. All-cause mortality, including early
mortality, was 20 (4.0%, 0.68%/patient-year): 8 cardiac
deaths, 6 malignancies, 1 suicide, 1 multiorgan failure after
noncardiac surgery, 1 renal failure, 2 bleeding events (hyper-
tensive cerebral hemorrhage, bleeding of esophageal varices),
and 1 intoxication. The cumulative overall survival compared
with the expected number of deaths of the age- and gender-
matched general German population is shown in Figure 1.
Morbidity
Five patients required the implantation of a permanent
pacemaker in the immediate postoperative period (14
days postoperatively).
Structural valve deterioration. Structural valve deteriora-
tion with impact on clinical functional capacity according to
the New York Heart Association was present in 8 patients.
Echocardiography revealed a relevant valvular impairment
in these patients (aortic regurgitation grade II or III, n ¼ 2;
increase of mean pressure gradient across the pulmonary ho-
mograft, n ¼ 6). In 6 patients a marked systolic left ventric-
ular impairment was observed without obvious valvular
dysfunction. Structural valve deterioration verified by re-
operation was present in 13 patients (9 autografts, 4 homo-
grafts; see Reoperation section).
Nonstructural dysfunction. Nonstructural valve dysfunc-
tion17 was confirmed in 2 homograft reoperations (1 pa-
tient–homograft mismatch, 1 annular ring dilatation) and 2
autograft reoperations (1 annular dilatation, 1 dilatation of
the sinotubular junction).
Valve thrombosis. One patient required reoperation on the
homograft 14 months after the primary procedure owing to
obstruction caused by extensive leaflet-adherent thrombi inrdiovascular Surgery c Volume 140, Number 4 817
TABLE 1. Patient demographics and preoperative characteristics
n 501
Mean age, y (range) 44.9  12.9 (13.8–70.5)
<20 19 3.8%
20–40 161 32.1%
41–60 274 54.7%
>60 47 9.4%
Gender
Male 384 76.6%
Female 117 23.4%
NYHA
I 144 28.7%
II 261 52.1%
III 93 18.6%
IV 3 0.6%
Ejection fraction (%)
>50 458 91.4%
30–50 42 8.4%
<30 1 0.2%
Diabetes mellitus 22 4.4%
Hypertension 168 33.5%
Impaired renal function 32 6.4%
Rhythm
Sinus 493 98.4%
Atrial fibrillation 7 1.4%
Pacemaker 1 0.2%
Hemodynamic diagnosis
Stenosis 73 14.6%
Regurgitation 148 29.5%
Mixed lesion 279 55.7%
Prosthetic valve
dysfunction
1 0.2%
Aortic valve morphology
Tricuspid 128 25.5%
Bicuspid 344 68.7%
Unicuspid 15 3.0%
Other 14 2.8%
Etiology
Congenital 345 68.9%
Degenerative 184 36.7%
Myxomatous 55 11.0%
Rheumatic 6 1.2%
Acute endocarditis 25 5.0%
Prior aortic valve
interventions
Valve replacement 6 1.2%
Valve reconstruction 13 2.6%
NYHA, New York Heart Association classification.
FIGURE 1. Probability of survival comparing the Ross subcoronary
patient group with the age- and gender-matched general population. CI,
95% confidence interval.
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D2 sinuses (despite the patient receiving aspirin). Addition-
ally, cusp laceration was present compatible with cured
endocarditis. Autograft valve thrombosis was not detected.
Embolism. Within 30 days postoperatively, stroke occurred
in 1 patient (day 5; treated with aspirin and unfractionated
heparin 22,500 IU/d) and a transient ischemic attack in 5
patients (all patients were treated with aspirin and unfractio-
nated heparin 22 500,IU/d).818 The Journal of Thoracic and Cardiovascular SurgAfter hospital discharge, 16 neurologic events occurred
(3.2%; LOR, 0.55%/patient-year; 7 strokes, 9 transient is-
chemic attacks). In 5 patients with stroke, new onset of atrial
fibrillation (without the patient receiving anticoagulation)
was present, and in 2 patients, carotid artery disease was
present. Transient ischemic attacks were associated with
atrial arrhythmias in 5 or carotid artery disease/thromboa-
theromatosis of the aortic arch in 4.
Noncerebral embolic event. There was 1 coronary embo-
lism complicated by refractory cardiogenic shock, leading
to a fatal outcome in the early postoperative period (see
Mortality). In 1 patient a thromboembolic femoral artery
occlusion was detected (sinus rhythm, mitral stenosis, no
anticoagulation).
Bleeding. Major internal or external bleeding occurred in 9
patients (1.8%; LOR, 0.31%/patient-year). One patient with
atrial fibrillation receiving oral anticoagulation therapy had
a head injury causing an epidural hematoma and 1 patient
without anticoagulation had a subdural hematoma after
a head trauma. Additionally, 1 patient receiving anticoagula-
tion had a subdural hematoma and another had gastrointesti-
nal bleeding. A hematothorax developed spontaneously in
a patient receiving anticoagulation. Additionally, 2 patients
with hemorrhages and fatal outcome (esophageal varices,
hypertensive cerebral bleeding; no anticoagulants in both pa-
tients) and 2 patients with gastrointestinal bleeding were not
treated with anticoagulants. Neither fatality was related to
the cardiac condition or specific cardiac drug therapy.
Antithrombotic management. At the time of the last foll-
ow-up visit, 35 patients were being treated with oral antico-
agulants (phenprocoumon; target international normalized
ratio, 2.5–3.0) for chronic or paroxysmal atrial fibrillation
(n ¼ 26), embolic events of vascular or cardiac originery c October 2010
FIGURE 2. Freedom from autograft reoperation. CI, 95% confidence
interval.
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D(n¼ 3), deep vein thrombosis (n¼ 3), pulmonary embolism
(n ¼ 2), and vascular surgery for chronic occlusive periph-
eral artery disease (n ¼ 1). Antiplatelet drug therapy
(100 mg aspirin daily) was used in all patients with coronary
artery disease or peripheral vascular disease (n ¼ 33). For
nonvalvular indications, 100 mg aspirin per day was used
in 16 patients.
Composite thrombosis, embolism, and bleeding. A total
of 34 patients had the composite end point of thrombosis,
embolism, and bleeding (6.8%; LOR, 1.16%/patient-year).
Operated valve endocarditis. No early endocarditis oc-
curred (<30 days). Late autograft endocarditis with severe
aortic regurgitation occurred in 5 patients (1.0%; LOR,
0.17%/patient-year): acute in 1, subacute in 2, and cured
in 2. In 2 patients a mechanical prosthesis was implanted,
and in another 3 a bioprosthesis. In 1 patient with additional
infective endocarditis of the homograft, the conduit was also
replaced by another homograft.
Homograft endocarditis occurred in 6 patients (1.2%;
LOR, 0.20%/patient-year): 3 with acute endocarditis (1 pa-
tient with autograft and homograft endocarditis), 1 with sub-
acute endocarditis, and 2 patients with valve destruction
present after cured infective endocarditis. In 1 patient recur-
rent homograft endocarditis had to be treated with a second
reoperation. In all cases the infected homograft was replaced
by another homograft. Recurrent homograft endocarditis
was treated with a stentless bioprosthesis.
One patient (not included in the above numbers) with pri-
mary mitral valve endocarditis after mitral valve replace-
ment with a bioprosthesis had trivalvular endocarditis with
involvement of the mitral bioprosthesis, the autograft, and
the homograft. He died 1 week after mitral valve replace-
ment in a septic shock state.
Medically treated valve endocarditis. Conservative
medical treatment of autograft endocarditis was successful
in 3 and homograft endocarditis in 4 patients (1.4%; LOR,
0.24%/patient-year).
The LOR for all operated and medically treated endocar-
ditis events was 0.65%/patient-year
Reoperation. Twenty-six reoperations on 28 Ross-related
valves (pulmonary autograft, pulmonary homograft) were
required in 23 patients (4.6%; 0.78%/patient-year); the
time interval between the initial procedure and the reopera-
tion was 4.82 4.00 years (range, 0.01–11.7 years; median,
2.85 years). Thirteen interventions in 10 patients (1 patient
had repeated interventions owing to recurrent infective en-
docarditis) were performed solely on the pulmonary conduit
(2.6%; LOR, 0.44%/patient-year). Twelve patients under-
went reinterventions on the autograft only (2.4%; LOR,
0.41%/patient-year) and 3 patients on both the autograft
and homograft (0.6%; LOR, 0.10%/patient year).
Indications for 15 autograft reinterventions (including in-
terventions on the autograft and homograft in 3 patients) in-
cluded structural valve failure with pure aortic regurgitationThe Journal of Thoracic and Cain 10 patients as well as aortic valve endocarditis in 5
patients (2 acute interventions for annular abscess without
regurgitation, 1 subacute, and 2 in patients with leaflet
perforation and moderate-to-severe aortic regurgitation
who were cured). Cusp prolapse (1 patient with acute endo-
carditis) was identified in 7 of 15 autograft reoperations (2/7
with concomitant annulus dilatation) and cusp perforations
(1 patient with endocarditis) was identified in 3 reoperations.
No reoperation owing to dilatation of the ascending aorta
was observed. There was no correlation between autograft
reoperation and valve morphologic features (bicuspid vs
tricuspid aortic valve; P ¼ .3). The autograft reoperation
procedures were performed from 0.01 to 11.7 years (mean,
5.31  4.25 years; median, 6.8 years) after the initial Ross
operation. In 7 patients a mechanical valve, in 6 a bioprosthe-
sis, and in 1 a homograft was implanted; in 1 patient an
autograft reconstruction was performed. Freedom from
reoperation on the autograft is displayed in Figure 2.
Among the 13 reinterventions on the pulmonary homo-
graft (including 3 patients with replacement of the autograft
and homograft and 1 patient with 3 reinterventions), 4
showed structural valve failure (in 4 pulmonary regurgita-
tion grade III, in 1 pulmonary stenosis), 2 had nonstructural
valve deterioration (patient–homograft mismatch in 1, annu-
lar dilatation in 1), and 7 had acute or cured infective endo-
carditis (2 with pure stenosis and 5 with pure regurgitation,
with grade III in 4 and grade IV in 1). The homograft reop-
eration procedures were performed from 1.1 to 11.7 years
(mean, 4.15 3.73 years; median, 2.2 years) after the initial
Ross operation. On 12 occasions another homograft was in-
serted; 1 patient with repeated homograft stenosis received
a Shelhigh bioprosthesis (Shelhigh, Inc, Union, NJ) that de-
generated within months and was replaced thereafter withrdiovascular Surgery c Volume 140, Number 4 819
FIGURE 4. Freedom from autograft and homograft reoperation. CI, 95%
confidence interval.
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Da Carbomedics artificial valve (Carbomedics, Inc, Austin,
Tex). No transcutaneous homograft procedures were per-
formed. Freedom from reoperation on the homograft is dis-
played in Figure 3. Freedom from autograft and homograft
reoperation is displayed in Figure 4. All patients survived
the reoperation on Ross-related valves and were alive at
the date of the last follow-up inquiry.
Major adverse valve-related events. Overall freedom
from any major valve-related event (all valve-related morta-
lity; valve-related morbidity: structural valve deterioration,
nonstructural valve dysfunction, thrombosis, bleeding,
embolism, neurologic events including transient ischemic
attacks, endocarditis, reintervention; and need for pace-
maker implantation within 14 days after operation17) was
95.8% at 1 year (95% confidence interval [CI], 94.0%–
97.6%), 90.1% at 5 years (95% CI, 87.4%–92.8%), and
81.8% at 10 years (95% CI, 76.9%–86.7%). The freedom
from each of the aforementioned events at 10 years is dis-
played in Table 2.
Functional and echocardiographic status at last follow-
up. Table 3 shows the functional capacity according to
the New York Heart Association classification and the echo-
cardiographic characteristics of the autograft and homograft
at the last follow-up visit. At 5 years postoperatively, free-
dom from aortic insufficiency of grade II or more, pulmo-
nary insufficiency of grade II or more, and homograft
stenosis with a mean gradient of 25 mm Hg or more was
94.6% (CI, 92.2%–99.9%), 94.6% (CI, 92.4%–100%),
and 95.2% (CI, 93.0%–100%), respectively, and at 10
years postoperatively 85.2% (CI, 80.3%–100%), 85.5%
(CI, 81.0%–100%), and 89.9% (CI, 86.0%–100%), re-
spectively. It must be stressed that the patients undergoing
reoperation, with their hemodynamics at the time of the
reoperation, are included in the aforementioned numbers.FIGURE 3. Freedom from homograft reoperation, CI, 95% confidence
interval.
820 The Journal of Thoracic and Cardiovascular SurgPatients with more than 10 years of follow-up. There
were 105 patients with more than 10 years of follow-up.
Of these patients, 5.3% had reoperations on the autograft
and 3.8% on the homograft compared with 2.3% and
1.8% of patients with follow-up less than 10 years, respec-
tively. The proportion of patients with aortic insufficiency of
grade 2 or more was 8.6% in patients with more than 10
years of follow-up and 3.5% for those with less than 10
years of follow-up.
DISCUSSION
This study provides some evidence that the life expectancy
of patients having the Ross operation is comparable with that
of the normal population, at least in the first decade after the
operation. This is astonishing to some extent inasmuch as the
patients had significant valvular disease before the operation
that may per se have a limiting effect on survival owing to
disease-related structural alterations within the myocardium
and connective tissue. However, patient selection by exclud-
ing those patients with severe heart failure, as well as the ex-
cellent postoperative hemodynamics with almost normal
pressure gradients across the autograft and in most cases neg-
ligible regurgitation in conjunction with the low risk of
valve-related extracardiac fatal events and the close regular
follow-up, may have a protective effect on patient survival.
In the full root technique, the adverse remodeling of the
pulmonary root leads to progressive dilatation and aortic
valve regurgitation, eventually mandating a reoperation in
some patients. The incidence of reoperations increases 7 to
8 years after the initial operation.9,10,15,16 In the present se-
ries, reoperations on the autograft were related to cusp pro-
lapse and not to autograft dilatation.
The second reason for reoperations on the autograft and
homograft was the occurrence of infective endocarditis.ery c October 2010
TABLE 2. Freedom from death and other morbid events at 10 years
Event Freedom (%) 95% CI
Death 94.7 91.8–97.6
SVD, nSVD with AG or HG reoperation 91.9 87.9–95.8
Endocarditis 94.2 91.1–100
Thromboembolism (including TIAs) 95.1 92.9–100
Thromboembolism (excuding. TIAs) 97.5 95.9–100
Major bleeding 97.0 94.5–100
CI, Confidence interval; SVD, structural valve deterioration; nSVD, nonstructural
valve deterioration; AG, autograft; HG, homograft; TIAs, transient ischemic attacks.
TABLE 3. Functional and echocardiographic outcome at last follow-
up visit
NYHA class
I 449 (93.9%)
II 27 (5.6%)
III 2 (0.4%)
IV 0
Unknown 0
Echocardiographic results
AG gradient, mean (mm Hg) AG regurgitation (grade)
<5 338 (73.0%) None 179 (38.7%)
5–10 119 (25.7%) Trivial 166 (35.9%)
>10 0 1/4 88 (19.0%)
Unknown 6 (1.3%) 2/4 24 (5.2%)
3/4 3 (0.6%)
4/4 0
Unknown 2 (0.4%)
HG gradient mean (mm Hg) HG regurgitation (grade)
<5 111 (23.8%) None 215 (46.0%)
5–10 240 (51.4%) Trivial 136 (29.1%)
11–15 66 (14.1%) 1/4 86 (18.4%)
16–20 25 (5.4%) 2/4 25 (5.4%)
21–25 12 (2.6%) 3/4 2 (0.4%)
>25 6 (1.3%) 4/4 0
Unknown 7 (1.5%) Unknown 3 (0.6%)
Deceased (n ¼ 20) and patients lost-to-follow-up (n ¼ 3) are excluded. Reoperated
valves are excluded from the corresponding valve function sections.
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DWhether this can be more favorably addressed with the ap-
propriate use of endocarditis prophylaxis remains specula-
tive. On the other hand, homograft degeneration with time
remains an issue; however, novel decellularization protocols
reducing the immunogenicity of homografts, with the poten-
tial to repopulate them with autologous cells, are promis-
ing.20 Although decellularized xenografts are reported to
yield excellent results in the right ventricular outflow tract,21
our own experience with decellularized homografts is lim-
ited and does not support these promising reports.22 This
may be related to the different decellularization protocols
and the fact that the allografts used in our study were addi-
tionally cryopreserved, which itself causes serious alter-
ations to the leaflet tissue.23
Taken together, the risk of reoperation is a weak point in
the Ross procedure. Although this risk is low (0.78%/
patient-year) for the observed time period of 0.1 to 14.1
years (mean, 5.9 3.6 years), it remains a matter of concern.
Seven of our 501 patients have borderline hemodynamics
(especially mean homograft gradients> 25 mm Hg) and
may become candidates for possible reoperations in the fu-
ture. Transfemoral approaches for pulmonary valve replace-
ment in case of homograft failure can potentially reduce the
need for conventional reoperations.24 Interestingly, there is
no exponential increase in reoperations in the longer term af-
ter 7 to 8 years, even in young patients, in contrast to reports
with the full root technique.9,10,15,16 However, the mean
follow-up duration of our patients was 6 years, and only lon-
ger-term results can give more definite information on this
subject. Although reoperation is a devastating problem for
the patient, there was no fatal outcome or increased morbidity
in our group during reoperations on the Ross-related valves.
Morbidity is low and bleeding complications are most prob-
ably related to anticoagulant medication prescribed not for the
Ross procedure itself but for other coexisting diseases, such as
atrial fibrillation. If this was taken into account in the reporting
guidelines, the incidence of strictly valve-related morbidity
after the Ross procedure would be even lower than reported
here, something that also holds true for bioprostheses.
Furthermore, quality of life is not considered, either in the
guidelines or in this article. There are, however, aspects of
quality of life, as measured by the 36 item Short-Form Health
Survey, that are advantageous in the Ross procedure25 com-The Journal of Thoracic and Capared with mechanical valves. These aspects are in addition
to freedom from noise disturbance26 and lifelong anticoagu-
lation as well as unrestricted daily activities (sports, profes-
sion, and nutrition). Female patients of child-bearing age
benefit from freedom from anticoagulation after the Ross pro-
cedure; for example, 8 female patients had uncomplicated
delivery of 12 children in our patient group. Mechanical
valve–related microembolism6 with the potential for continu-
ous cognitive impairment27 is not considered in the new
guidelines. Also not taken into account are hemodynamics
like the near normal transvalvular pressure gradients at rest
and exercise in Ross patients,28 left ventricular mass regres-
sion,18 and near normal flow turbulence characteristic down-
stream from the autograft,29 in contrast to the altered
coronary flow reserve in patients with mechanical valves.30
Besides these objective parameters, how can we grade and
evaluate the fear of a patient for adverse events after the
Ross operation (mainly the need for reoperation), which
does not occur suddenly and has a low risk of mortality
and morbidity? On the other hand, there is the fear of sudden
unexpected major events with a mechanical valve, mainly
involving extracardiac organs, with the potential of lifelong
disability (eg, stroke). How should we objectively measure
the shortcomings of anticoagulation-related minor problems,
such as troubles and uncertainties during dental procedures,
nose bleeding, and minor and major accidents?
In conclusion, our experience with 501 subcoronary Ross
operations shows excellent clinical and hemodynamic resultsrdiovascular Surgery c Volume 140, Number 4 821
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observed time period of 0.1 to 14.1 years (mean, 5.9  3.6
years). The selection bias makes the comparison of the Ross
operation with mechanical valves or bioprostheses difficult.
The use of randomization or propensity scoring techniques
seems indispensible for comparison of the Ross operation
with other alternatives. Although a certain risk for reoperation
does exist with the subcoronary technique, for the observed
time period of 0.1 to 14.1 years (mean, 5.9 3.6 years) post-
operatively this risk remains low and no exponential increase
of the reoperation rate with time is observed, in contrast to the
full root technique.9,10,15,16 In general, candidates for aortic
valve replacement have to be thoroughly informed about the
full spectrum of the aforementioned aspects. That holds true
for the Ross operation and also for all other alternatives. Deci-
sion-making is difficult and is related not only to the valve sub-
stitute per se but also to the attitude of the patient, the surgeon/
cardiologist, and the technical details and postoperative care.
All substitutes have their intrinsic advantages and disadvan-
tages; we are far from an ideal solution. All efforts have to
be concentrated on improving implants and techniques. For
the final judgment of the subcoronary method reported in
this article, there is no doubt that longer-term follow-up studies
are needed.References
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E-APPENDIX
Surgical Technique
1. Aortotomy and inspection of the aortic valve. The aorto-
tomy is S-shaped, reaching into the noncoronary sinus, espe-
cially in patients with bicuspid aortic valves, because in
these cases the noncoronary sinus is usually enlarged and
can be adjusted by later aortotomy closure to the size of
the autograft. If the sinotubular junction or the ascending
aorta is larger than 50 mm, the ascending aorta is replaced
by a supracommissural tube graft. Extensive and meticulous
decalcification is necessary. The root anatomy of a tricuspid
valve provides excellent conditions for the autograft implan-
tation; bicuspid aortic valves, types I and II,E1 have favor-
able root anatomy, whereas a subcoronary Ross procedure
in a root of a bicuspid aortic valve type 0 is challenging
and, in view of alternative substitutes, questionable. Hegar
dilators are used for measurement of the size of the root.
The sinotubular junction should be at least the same size
as the tailored annulus (see later); some millimeters larger
is of no concern, because resistance against dilatation-asso-
ciated regurgitation is well preserved in autografts.E2 A sino-
tubular junction diameter after implantation smaller than that
of the autograft in the pulmonary position is potentially
a risk factor for cusp prolapse–induced aortic insufficiency.
This can be prevented by a small pericardial patch, normally
1 cm in width in the aortotomy suture line if necessary, or by
not incising the noncoronary sinus during aortotomy. If the
maximal diameter of the sinotubular junction or ascending
aorta is larger than 50 mm, the ascending aorta is replaced
by a supracommissural tube graft.
2. Excision of the pulmonary autograft. The trunk of the
main pulmonary artery is incised anteriorly, half circum-
ferentially and 0.5 cm distal to the anterior commissure, al-
lowing for inspection of the valve. Large fenestrations,
thickened and retracted leaflet tissue, and quadricuspid
valves are considered contraindications. Only slight dispro-
portions of leaflets and sinuses are accepted and adjusted by
adequate positioning of the autograft in the aortic root. The
pulmonary trunk is transected completely and tilted anteri-
orly to dissect the plane between the adventitia and the pul-
monary trunk posteriorly. Care must be taken to stay close to
the autograft. Usually an Overholt forceps placed through
the pulmonary valve into the right ventricular outflow tract,
indicating a level of 2 mm beneath the pulmonary annulus, is
used to determine the right ventricular cross-sectional inci-
sion line. This incision is continued close to the semilunar
attachment of the leaflets, trying to find a dissection plane
posteriorly between the valve and right ventricular muscle.
Special care has to be taken at the left lateral aspect of this
dissection plane, where a typical right ventricular outflow
tract muscle bundle indicates the position of the first septal
branch (Merrick AF, Yacoub MH, Ho SY, Anderson RH.
Anatomy of the muscular subpulmonary infundibulum
with regard to the Ross procedure. Ann Thorac Surg.
2000;69:556-61) (Figure E1). The dissection at this area
has to be kept very close to the pulmonary annulus, leaving
only a small amount of muscle at the autograft. At this stage,
there is a risk that the dissection level is too deep, causing
problems with the coronary septal branches. After excision
of the autograft, left coronary artery cardioplegia is given to
identify and treat bleeding sites. The autograft is trimmed,
leaving only a 1- to 2-mm rim of muscular tissue while in-
dicating the midpoint of the interleaflet triangles by a small,
slightly scalloped incision (Figure E2).
3. Implantation of the pulmonary autograft. Normally the
proximal autograft implantation suture line follows the
scalloped semilunar attachment of the former aortic valve
leaflets half the distance up to the commissure, usually
starting at the left coronary sinus (Figure E3). The stitches
in the autograft (4-0 polyfilament material) are placed di-
rectly at or through the attachment of pulmonary leaflets
(Figure E4) following a line congruent to that in the aortic
root, as shown in Figure E3. The autograft is placed side
by side to the aortic root (Figure E5). The inversion tech-
nique may cause leaflet distortion. We start with a U-stitch
followed by 3 regular single over-and-over stitches, and
again the next series starts with a U-stitch (Figure E6).
The U-stitches are very practical for later traction and
positioning of the autograft into the aortic root. If the
diameter of the annulus is more than roughly 25 mm,
a 2-0 polytetrafluoroethylene suture (Gore-Tex suture;
W. L. Gore & Associates, Inc, Flagstaff, Ariz) or Dacron
strip is integrated in the suture line during tying of the
knots. This polytetrafluoroethylene or Dacron strip is
held under tension at each suture segment (1 U-stitch, 3
single stitches) so as to fix the annulus diameter or even
reduce it (Figure E7). If a polytetrafluoroethylene 2-0 su-
ture is used, both ends of these sutures are placed outside
the nadir of the noncoronary cusp and fixed over a Teflon
patch. Alternatively, the interleaflet trigone between the
noncoronary and left coronary sinus can be plicated by
a U-stitch from outside to reduce the size of the annulus.
Next, 5-0 polypropylene U-stitches (Prolene; Ethicon, Inc,
Somerville, NJ) buttressed with, for example, autologous
pericardial pledgets inside and Teflon patches outside, are
used to fix the commissures exactly above the former com-
missures of the aortic valve, trying to lift up the commis-
sures, commonly by about 1 cm (Figure E8). Only small
parts the left and right coronary sinuses of the autograft
are excised before the attachment of the autograft sinuses
in a subcoronary fashion to the sinuses of the aortic valve
with a 5-0 Prolene polypropylene suture starting at the left
coronary sinus—always at the most remote point from the
surgeon—in a running over-and-over suture technique to-
ward the surgeon. This is followed by the other end of
the suture stitched in an inside–outside fashion through
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the wall of the aortic root, up to the commissure between
the left and right coronary ostia (Figure E9).
4. Implantation of the pulmonary homograft. In almost all
cases a long (up to the bifurcation) pulmonary homograft is
used. The muscular tissue of the allograft is excised as
much as possible, leaving only 2 or 3 mm of allogenic myo-
cardium or replacing the complete muscle rim of the allograft
by a pericardial or polytetrafluoroethylene strip. Latest inves-
tigations show only minor superiority of the pericardial
patch,3,11 leading to it now being applied only in small-sized
homografts. The distal suture line is performed with 5-0 Pro-
lene polypropylene suture whereby the stitches are placed
close together to ameliorate constriction by the suture line.
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For the proximal anastomosis, 5-0 or 4-0 Prolene polypropyl-
ene sutures, depending on the allograft material, are used,
with special care not to injure the area of the septal branch
where the stitches are placed superficially. The size of the ho-
mograft is chosen to be 25 mm in diameter or larger.
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FIGURE E1. Excision of the autograft. Usually a muscle band (X) in the
right ventricular outflow tract indicates the location of the septal branches
(tip of scissors).
FIGURE E2. Preparation of the autograft. The autograft is trimmed leav-
ing only a 1- 2-mm rim of muscular tissue and incising the interleaflet tri-
angle slightly in a scalloped fashion.
FIGUREE3. Implantation of the autograft. This schematic drawing shows
the suture line (broken red lines) following the attachment of the former aor-
tic valve leaflets halfway up to the commissures.
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FIGURE E4. Implantation of the autograft. Sutures of the proximal suture
line are placed close to the scalloped attachment of the semilunar leaflets of
the pulmonary autograft.
FIGURE E5. Implantation of the autograft. The autograft (A) is sutured
side by side to the annulus of the aortic root (AR).
FIGURE E6. Implantation of the autograft. One U-stitch is used first, fol-
lowed by 3 over-and-over single stitches. This series of sutures is then
repeated all around the annulus (A, autograft; AR, aortic root). The
U-stitches are helpful for traction and positioning the autograft into the root.
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FIGURE E7. Implantation of the autograft. A strip of polytetrafluoroethy-
lene or a 2-0 polytetrafluoroethylene suture is integrated in the proximal
suture line to reduce and stabilize a dilated annulus.
FIGURE E8. Implantation ofthe autograft. The commissure of the auto-
graft (1) is hitched up roughly 1cm above the commissure of the correspond-
ing aortic root (2).
FIGURE E9. Implantation of the autograft. The distal sinus suture line us-
ing 5-0 Prolene polypropylene continuously is completed. A pericardial
patch (X) is integrated in this case into aortotomy closure line to adjust a nar-
rowed sinotubular junction of the aortic root to the autograft dimensions.
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